1. Evaluation of new migrastatin and dorrigocin congeners unveils cell migration inhibitors with dramatically improved potency.
- Author
-
Ju J, Rajski SR, Lim SK, Seo JW, Peters NR, Hoffmann FM, and Shen B
- Subjects
- Animals, Antibiotics, Antineoplastic chemistry, Cell Movement drug effects, Drug Design, Female, Humans, Macrolides chemistry, Mice, Molecular Structure, Piperidones chemistry, Structure-Activity Relationship, Antibiotics, Antineoplastic chemical synthesis, Antibiotics, Antineoplastic pharmacology, Macrolides chemical synthesis, Macrolides pharmacology, Piperidones chemical synthesis, Piperidones pharmacology
- Abstract
Lactimidomycin (LTM, 1), iso-migrastatin (iso-MGS, 2) and migrastatin (MGS, 3) are macrolide antitumor antibiotics differing in macrolide ring size but all bearing a glutarimide side chain. To further develop these natural products and related analogs as drug candidates we have produced and evaluated the biological activities of a small library of iso-MGS and LTM-derived agents; congeners evaluated bear either the MGS scaffold or related acyclic (dorrigocin) scaffolds. Scratch wound-healing (SWH) assays with 4T1 mouse and MDA-MB-231 human mammary tumor cell lines, respectively, reveal structural elements crucial to inhibition of cell migration by these compounds. Moreover, two substances, 14 and 17, with activity far superior to that of MGS are unveiled by SWH assays.
- Published
- 2008
- Full Text
- View/download PDF